A Review on Alzheimer's Disease: Epidemiology, Etiology, Diagnosis, Management Strategies and Treatment Modalities
DOI:
https://doi.org/10.22270/ajprd.v12i4.1433Abstract
One of the most debilitating brain ailments that affect older people is Alzheimer's disease. It is a condition that is underdiagnosed, undertreated, and rapidly becoming into a significant public health issue. Over the past ten years, there has been a consistent increase in the amount of work done to identify the disease's etiology and create pharmacological treatments. Improved clinical diagnostic standards and better behavioural and cognitive disturbance treatments are recent breakthroughs. Randomised, double-blind, placebo-controlled, parallel-group studies assessing performance-based assessments of cognitive function, activities of daily living, and behaviour have clinically assessed symptomatic treatment, mostly focussing on cholinergic therapy. Galantamine, donepezil, tacrine, rivastigmine, and other cholinesterase inhibitors are among the medications that are advised for treating cognitive impairment in Alzheimer's patients. It is debatable and requires further research to determine the function of antioxidants, anti-inflammatory drugs, and oestrogen replacement. Behavioural disturbances are treated with antidepressants, antipsychotics, mood stabilisers, anxiolytics, and hypnotics. The development of new classes of medications that target different neurotransmitter systems (cholinergic, glutamatergic, etc.) for the treatment of behavioural disturbances and cognitive deficits, as well as the development of preventive measures like amyloid p-peptide immunisations and inhibitors of β-secretase and γ-secretase, are some of the future directions in research and treatment of patients with Alzheimer's disease.
Downloads
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stacllan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–91.
Small GW., Rabins PV., Bary PP., et al. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363–1371.
Poorkaj P., Bird TD., Wisjsman E., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815–825.
Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid p-peptide in the brain and cognitive decline. JAMA. 2000;283:1571–1577.
Mooser V., Helbecque N., Miklossy J., Marcovina SM., Nicod P., Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer's disease. Ann Intern Med. 2000;132: 533–537.
Andersen K., Launer LJ., Dewey ME., et al. Gender differences in the incidence of Alzheimer's dementia and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53: 1992–1997.
Launer LJ., Andersen K., Dewey ME., et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52:78–84.
Mehlman MJ., Kodish ED., Whitehouse P., et al. The need for anonymous genetic counseling and testing. Am J Hum Genet. 1996;58:393–397.
Lapham EV., Kozma C., Weiss JO. Genetic discrimination. Science. 1996;274:621–624.
Gao S., Hendric HC., Hall KS., et al. The relationship between age, sex, and the incidence of dementia and Alzheimer Disease. Arch Gen Psychiatry. 1998;55:809–815.
American Psychiatric Association. Practice Guidelines for the treatment of patients with Alzheimer's Disease and other dementias of late life. Am J Psychiatry. 1997;154(suppl 5):1–39.
Mittleman MS., Feris SH., Shulman E., et al. A family intervention to delay nursing home placement of patients with Alzheimer's disease: a randomized controlled trial. JAMA. 1996;276:1725–1731.
Stern Y., Tang MX., Albert M., et al. Predicting time to nursing home care and death in individuals with Alzheimer's disease. JAMA. 1997;277:806–812.
Schachter AS., Davis KL. Alzheimer's disease. Curr Treat Options Neurol. 2000;2:51–60.
Schachter AS., Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs. 1999;11:281–288.
Rogers SL., Doody RS., Mohs RC., Friedhoff LZT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021–1031.
Shintani EY., Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm. 1998;54:2805–2810.
Rogers SL., Farlow MR., Doody RS., et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136–145.
Rogers SL., Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol. 1998;8:67–75.
Burns A., Rossor M., Hecker J., Gautier S., et al. The effects of donepezil in Alzheimer's disease: results form a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237–244.
Samuels SC., Davis KL. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Drug Saf. 1997;16:66–77.
Davis KL., Thai LJ., Gamzu ER., et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;327:1253–1259.
Gracon SI., Knapp MJ., Berghoff WG., et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord. 1998;12:93–101.
Knapp MJ., Knopman DS., Solomon PR., Pendlebury WW., Davis CS., Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994;271:985–991.
Thomsen T., Bickel U., Fischer JP., et al. Galanthamine hydrobromide is a long-term treatment of Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther. 1995;274:767–770.
Parys W., Pontecorvo M J. Treatment of Alzheimer's disease with galanthamine, a compound with a dual mechanism of action. Janssen Research Foundation. 1998 Data on file.
Bores GM., Huger FP., Petko W., et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1998;277:728–738.
Sramek JJ., Anand R., Wardle TS., et al. Safety/tolerability trial of SDZ ENA713 in patients with probable Alzheimer's disease. Life Sci. 1996;58:1201–1207.
Anand R., Gharabawi G., Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Prac. 1999;8:109–116.
Rosier M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999;318:633–640.
Davis KL., Mohs RC., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer Disease. JAMA. 1999;281:1401–1406.
Raskind MA., Sadowsky CH., Sigmund WR., et al. Effects of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol. 1997;54:836–840.
Raskind MA. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. J Clin Psychiatry. 1998;59(suppl 9):28–39.
Pettenati C., Donate MF. Behavioral symptoms of Alzheimer's disease: improvement by donepezil. Paper presented at: 6th International Conference on Alzheimer's Disease and Related Disorders; July 18-23, 1998. Amsterdam, The Netherlands. 1998.
Hausserman P., Reinbold H., Schroder SG. Benefit of cognition enhancers on noncognitive features of dementia Paper presented at: 6th International Conference on Alzheimer's Disease and Related Disorders; July 18-23, 1998. Amsterdam, The Netherlands. 1998.
Nordberg A., Svenson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 1998;19:465–480.
Schmidt R., Fazekas F., Reinhart B., et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc. 1996;44:1307–1313.
Henderson VW., Paganini-Hill A., Emmanuel CK., et al. Estrogen replacement therapy in older women: comparison between Alzheimer's disease cases and non-demented control subjects. Arch Neurol. 1994;51:896–900.
Paganini-Hill A., Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med. 1996;156:2213–2217.
Asthana S., Craft S., Baker LD., et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind pilot study. Psychoneuroendocrínology. 1999;24:657–677.
Mulnard RA., Cotman CW., Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007–1015.
Henderson VW., Paganini-Hill A., Miller BL., et al. Estrogen for Alzheimer's disease in women. Randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295–301.
Stewart WF., Kawas C., Corrada M., Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626–632.
Breitner JC., Gau BA., Welsh KA., et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994;44:227–232.
Veld BA., Launer LJ., Hoes AW., et al. NS AIDs and the incidence of Alzheimer's disease. 6th International Conference on Alzheimer's Disease and Related Disorders; July 18-23, Amsterdam, The Netherlands. 1998.
Rogers J., Kirby LC., Hempelman SR., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609–1611.
Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's Disease. Neurology. 1999;53:197–201.
Aisen PS., Marin D., Altseil L., et al. A pilot study of prednisone in Alzheimer's disease. Dementia. 1996;7:201–206.
Aisen PS., Davis KL., Berg JD., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 2000;54:588–595.
Aisen PS., Altsteil L., Marin D., et al. Treatment of Alzheimer's disease with prednisone: results of pilot studies and design of multicenter trial [abstract]. J Am Geríatr Soc. 1995;43:SA27.
Thai L. A multicenter trial of rofecoxib and naproxen in Alzheimer's disease. 2000. In press.
Riekkinen PJ. Review on the long-term efficacy and safety of selegiline in the treatment of Alzheimer's disease. Paper presented at: 6th International Conference on Alzheimer's Disease and Related Disorders; July 1823, 1998. Amsterdam, The Netherlands. 1998.
Tariot PN., Goldstein B., Podgorski CA., et al. Short-term administration of selegiline for mild to moderate dementia of the Alzheimer's type. Am J Geriatr Psychiatry. 1998; 6:145–154.
Filip V., Kolibas E. Selegiline in the treatment of Alzheimer's disease: a longterm randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer type Study Group. J Psychiatry Neurosci. 1999; 24:234–243.
Sano M., Ernesto C., Thomas RG., Klauber MR., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997; 336:1216–1222.
Nair NP., Amin M., Holm P., et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord. 1995; 33:1–9.
Schweitzer E., Rickels K., Hassman H., et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clín Psychiatry. 1998; 59:175–183.
Taragano FE., Lyketsos CG., Mangone CA., Allegri RF., Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997; 38:246–252.
Katona CL., Hunter BN., Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13:100–108.
Olafsson K., Jorgensen S., Jensen HV., Bille A., Arup P., Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992;85:453–456.
Pollock BG., Mulsant BH., Sweet R., et al. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry. 1997;5:70–78.
Burke WJ., Dewan V., Wengel SP., et al. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geríatr Psych. 1997;12:519–525.
Schneider LS., Pollack VE., Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geríatr Soc. 1990;38:553–563.
Katz IR., Jeste DV., Mintzer JE., Clyde C., Napolitano J., Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107–115.
De Deynn PP., Rabheru K., Rasmussen A., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946–955.
Street J., Clark WS., Gannon KS., Miran S., Sanger T., Tollefson GD. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. 1999 Annual Meeting New Research Program and Abstracts. Washington, DC: American Psychiatric Association; 1999:225–226.
McManus DQ., Arvanitis LA., Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999;60:292–298.
Devanand DP., Marder K., Michaels KS., et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behavior in Alzheimer's disease. Am J Psychiatry. 1998; 155:1512–1520.
Neumann PJ., Herman RC., Kuntz KM., et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's Disease. Neurology. 1999; 52:1138–1145.
Wimo A., Karlsson G., Nordberg A., et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord. 1997; 11:191–200.
Davis KL. Future therapeutic approaches to Alzheimer's Disease. J Clin Psychiatry. 1998; 59(suppl ):11,14–16.
Kuhl DE., Koeppe RA., Minoshima S., et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999; 52:691–699.
Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid beta attenuates Alzheimer-disease like pathology in the PDAPP mouse. Nature. 1999;400:173–177.
Vassar R., Bennett BD., Babu-Khan S., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–741.
Lichtentaler SF., Wang R., Grimm H., Uljon SN., Masters CL., Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci dSA. 1999;96:3053–3058.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Priyanka Tanwar, Mamta Naagar, Manish Kumar Maity
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.